Alexander Winkelmann

Gehlsheimer Str. 20
Rostock, MV 18147, Germany

Last Updated: 09/26/2026

Save publications for later

Sign Up

Not sure about your diagnosis?

Check Your Symptoms

Found 55 publications

Tetanus and Diphtheria Toxoid-Containing Vaccine in Multiple Sclerosis Patients: A Real-World Prospective, Open-Label, Multi-Centre Study.

Tetanus and Diphtheria Toxoid-Containing Vaccine in Multiple Sclerosis Patients: A Real-World Prospective, Open-Label, Multi-Centre Study.

Journal: Vaccines

Published: March 12, 2025

Apheresis for the treatment of relapses in MS and NMOSD: reduced antibody reactivities, gene expression changes and potential clinical response indicators.

Apheresis for the treatment of relapses in MS and NMOSD: reduced antibody reactivities, gene expression changes and potential clinical response indicators.

Journal: Frontiers in immunology

Published: November 20, 2024

Apheresis therapies in MOGAD: a retrospective study of 117 therapeutic interventions in 571 attacks.

Apheresis therapies in MOGAD: a retrospective study of 117 therapeutic interventions in 571 attacks.

Journal: Journal of neurology, neurosurgery, and psychiatry

Published: August 19, 2024

Visual quality of life in NMOSD and MOGAD: profiles, dynamics and associations with ageing and vision.

Visual quality of life in NMOSD and MOGAD: profiles, dynamics and associations with ageing and vision.

Journal: Journal of neurology

Published: July 08, 2024

Differential gene expression in B cells and T helper cells following high-dose glucocorticoid therapy for multiple sclerosis relapse.

Differential gene expression in B cells and T helper cells following high-dose glucocorticoid therapy for multiple sclerosis relapse.

Journal: Biomedicine & pharmacotherapy = Biomedecine & pharmacotherapie

Published: March 05, 2024

Time to Disability Milestones and Annualized Relapse Rates in NMOSD and MOGAD.

Time to Disability Milestones and Annualized Relapse Rates in NMOSD and MOGAD.

Journal: Annals of neurology

Published: September 08, 2023

Side effects following vaccination in multiple sclerosis: a prospective, multi-centre cohort study.

Side effects following vaccination in multiple sclerosis: a prospective, multi-centre cohort study.

Journal: Scientific reports

Published: May 07, 2023

Transcriptome alterations in peripheral blood B cells of patients with multiple sclerosis receiving immune reconstitution therapy.

Transcriptome alterations in peripheral blood B cells of patients with multiple sclerosis receiving immune reconstitution therapy.

Journal: Journal of neuroinflammation

Published: October 12, 2022

Correlation of Nabiximols Dose to Steady-State Concentrations of Cannabinoids in Urine Samples from Patients with Multiple Sclerosis.

Correlation of Nabiximols Dose to Steady-State Concentrations of Cannabinoids in Urine Samples from Patients with Multiple Sclerosis.

Journal: Journal of clinical medicine

Published: March 22, 2022

Vaccination and immunotherapies in neuroimmunological diseases.

Vaccination and immunotherapies in neuroimmunological diseases.

Journal: Nature reviews. Neurology

Published: March 10, 2022

The risk of infections for multiple sclerosis and neuromyelitis optica spectrum disorder disease-modifying treatments: Eighth European Committee for Treatment and Research in Multiple Sclerosis Focused Workshop Review. April 2021.

The risk of infections for multiple sclerosis and neuromyelitis optica spectrum disorder disease-modifying treatments: Eighth European Committee for Treatment and Research in Multiple Sclerosis Focused Workshop Review. April 2021.

Journal: Multiple sclerosis (Houndmills, Basingstoke, England)

Published: February 24, 2022

Implication of genetic variants in primary microRNA processing sites in the risk of multiple sclerosis.

Implication of genetic variants in primary microRNA processing sites in the risk of multiple sclerosis.

Journal: EBioMedicine

Published: December 02, 2021

Showing 1-12 of 55

Last Updated: 09/26/2026